# Genesis Molecular AI (formerly Genesis Therapeutics)

Source: https://onco.cc/companies/genesis-molecular-ai/  
OnCo record `genesis-molecular-ai` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Genesis Molecular AI does small-molecule discovery on its GEMS platform, which combines physics and deep learning, with oncology programmes in the clinic pipeline.

## Summary

Genesis Molecular AI, formerly Genesis Therapeutics and based in Burlingame, California, does small-molecule discovery on its GEMS platform, which combines physics and deep learning, with oncology programmes in its clinic-bound pipeline. It holds partnerships with Genentech, Lilly, Gilead and Incyte and rebranded in 2025. OnCo links it to AI-driven drug and target discovery. Whether physics-informed models find small molecules for targets that conventional screening missed is the question its pipeline will answer. The AI-driven drug discovery page carries the wider field.

## Fields

- Kind: Company
- Last checked: 2026-09-08
- Tags: ai
- HQ: Burlingame, CA
- Type: biotech
- Website: https://www.genesistherapeutics.ai

## Sources

- Official website: https://www.genesistherapeutics.ai

## Connected records

- fronts: [Drug Discovery Platforms](https://onco.cc/fronts/drug-discovery/)
- companies: [Incyte](https://onco.cc/companies/incyte/)
- technologies: [AI-driven drug & target discovery](https://onco.cc/technologies/ai-drug-design/)

---
JSON: https://onco.cc/api/v1/entities/genesis-molecular-ai.json